PMID- 30958710
OWN - NLM
STAT- MEDLINE
DCOM- 20201030
LR  - 20201030
IS  - 1471-1753 (Electronic)
IS  - 0954-6634 (Linking)
VI  - 31
IP  - 7
DP  - 2020 Nov
TI  - Long-term effects of biologic therapies on peripheral blood eosinophils in 
      patients with psoriasis: a 3-year single-center study.
PG  - 702-706
LID - 10.1080/09546634.2019.1605139 [doi]
AB  - Background: Biologic therapies (BTs), etanercept, infliximab, adalimumab, and 
      ustekinumab, are generally well-tolerated and safe agents in psoriasis 
      management.Objectives: To determine the overall effect of BTs on peripheral blood 
      eosinophil count (PBEc) and percentage (PBEp), peripheral blood basophil count 
      (PBBc) and percentage (PBBp), white blood cell count (WBCc), erythrocyte 
      sedimentation rate (ESR), and serum C-reactive protein (s-CRP) level during a 
      3-year follow-up in patients with psoriasis.Methods: This retrospective cohort 
      study included 200 patients (116 men; 84 women) treated continuously with BTs for 
      3 years for plaque-type, pustular, or nail psoriasis. Patient data were reviewed 
      from medical charts. During routine laboratory investigation at baseline and 
      every 3 months thereafter up to 3 years, the PBEp, PBEc, PBBp, PBBc, WBCc, ESR, 
      and s-CRP level were monitored. Generalized estimating equations were used to 
      compare consecutive data.Results: Seventy patients received infliximab (35%); 34 
      (17%), etanercept; 44 (22%), adalimumab; and 52 (26%), ustekinumab. The mean PBEp 
      and PBEc significantly increased starting from 3 months after BT (both p<.001). 
      The mean PBEp and PBEc significantly increased during follow-up compared with the 
      baseline values (PBEp (%): 1.49 +/- 0.1 (1st month) vs. 2.29 +/- 0.14 (3rd month), 
      p<.001 and 1.49 +/- 0.1 (1st month) vs. 2.17 +/- 0.18 (36th month), p=.004; PBEc 
      (x10(3)/microL): 115.80 +/- 6.32 (1st month) vs. 174.9 +/- 10.08 (3rd month), p<.001 and 
      115.80 +/- 6.32 (1st month) vs. 162.9 +/- 12.86 (36th month), p<.001). However, the 
      mean PBBp, PBBc, WBCc, ESR, and s-CRP level did not change 
      significantly.Conclusions: The PBEc and PBEp increase with BTs up to 3 years in 
      patients with psoriasis. This increase is observed at as early as 3 months of BT 
      and maintained thereafter.
FAU - Akdogan, Neslihan
AU  - Akdogan N
AUID- ORCID: 0000-0002-1137-5399
AD  - Department of Dermatology and Venereology, School of Medicine, Hacettepe 
      University, Ankara, Turkey.
FAU - Dogan, Sibel
AU  - Dogan S
AUID- ORCID: 0000-0002-5383-6886
AD  - Department of Dermatology and Venereology, School of Medicine, Hacettepe 
      University, Ankara, Turkey.
FAU - Atakan, Nilgun
AU  - Atakan N
AUID- ORCID: 0000-0003-3700-514X
AD  - Department of Dermatology and Venereology, School of Medicine, Hacettepe 
      University, Ankara, Turkey.
LA  - eng
PT  - Journal Article
DEP - 20190501
PL  - England
TA  - J Dermatolog Treat
JT  - The Journal of dermatological treatment
JID - 8918133
RN  - B72HH48FLU (Infliximab)
RN  - FU77B4U5Z0 (Ustekinumab)
RN  - FYS6T7F842 (Adalimumab)
RN  - OP401G7OJC (Etanercept)
SB  - IM
MH  - Adalimumab/pharmacology/therapeutic use
MH  - Adult
MH  - *Biological Therapy
MH  - Eosinophils/*drug effects
MH  - Etanercept/pharmacology/therapeutic use
MH  - Female
MH  - Humans
MH  - Infliximab/pharmacology/therapeutic use
MH  - Longitudinal Studies
MH  - Male
MH  - Middle Aged
MH  - Psoriasis/blood/drug therapy/*immunology
MH  - Retrospective Studies
MH  - Ustekinumab/pharmacology/therapeutic use
OTO - NOTNLM
OT  - Psoriasis
OT  - biologics
OT  - eosinophil
EDAT- 2019/04/09 06:00
MHDA- 2020/10/31 06:00
CRDT- 2019/04/09 06:00
PHST- 2019/04/09 06:00 [pubmed]
PHST- 2020/10/31 06:00 [medline]
PHST- 2019/04/09 06:00 [entrez]
AID - 10.1080/09546634.2019.1605139 [doi]
PST - ppublish
SO  - J Dermatolog Treat. 2020 Nov;31(7):702-706. doi: 10.1080/09546634.2019.1605139. 
      Epub 2019 May 1.